PT  - JOURNAL ARTICLE
AU  - HIROAKI AKAMATSU
AU  - YUICHI OZAWA
AU  - JUN OYANAGI
AU  - DAICHI FUJIMOTO
AU  - AKITO HATA
AU  - NOBUYUKI KATAKAMI
AU  - KEISUKE TOMII
AU  - ERIKO MURAKAMI
AU  - TAKEYA SUGIMOTO
AU  - TOSHIO SHIMOKAWA
AU  - YASUHIRO KOH
AU  - NOBUYUKI YAMAMOTO
TI  - Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation
AID  - 10.21873/anticanres.14844
DP  - 2021 Feb 01
TA  - Anticancer Research
PG  - 911--917
VI  - 41
IP  - 2
4099  - http://ar.iiarjournals.org/content/41/2/911.short
4100  - http://ar.iiarjournals.org/content/41/2/911.full
SO  - Anticancer Res2021 Feb 01; 41
AB  - Background/Aim: To explore the safety of osimertinib plus ramucirumab in patients with EGFR-mutated lung adenocarcinoma. Patients and Methods: Six advanced lung adenocarcinoma patients with EGFR mutation were treated with osimertinib 80 mg/day plus ramucirumab 10 mg/kg, every two weeks. Defined dose-limiting toxicity (DLT) was assessed within the first two treatment cycles. Results: Of those enrolled, five patients had both EGFR exon 20 T790M mutation and sensitizing mutation. DLT was observed in one patient (grade 3 appetite loss). During the entire period, no other severe adverse event was observed. Five patients showed partial response and one disease progression. Median progression-free survival for patients with EGFR T790M was 9.2 months. In an exploratory analysis, changes of cell-free DNA at 2 weeks predicted radiological tumor responses. Conclusion: The safety results of osimertinib plus ramucirumab in Japanese lung adenocarcinoma patients with EGFR mutation will lead to further efficacy investigation.